Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis
NCT07059130
·
clinicaltrials.gov ↗
PHASE4
Phase
NOT_YET_RECRUITING
Status
150
Enrollment
INDUSTRY
Sponsor class
Conditions
Crohn Disease (CD)
Crohns Disease
Ulcerative Colitis (UC)
Interventions
BIOLOGICAL:
Mirikizumab
Sponsor
Rubix LS
Collaborators
[object Object]